U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination (NYSE:LLY)

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, an investigational compound being studied for the treatment of adults with type 2 diabetes (T2D). Empagliflozin plus metformin is part of the Boehringer Ingelheim and Eli Lilly and Company(NYSE: LLY) Diabetes alliance portfolio.



U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination (NYSE:LLY)